Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci

Bente Glintborg, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard Andersen, Jolanta Grydehøj, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland

Open source

DOI: 10.1136/annrheumdis-2018-214788
Published: 2020-02
Container: Annals of the Rheumatic Diseases
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/annrheumdis-2018-214788,
  title = {Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci},
  author = {Bente Glintborg and Anne Gitte Loft and Emina Omerovic and Oliver Hendricks and Asta Linauskas and Jakob Espesen and Kamilla Danebod and Dorte Vendelbo Jensen and Henrik Nordin and Emil Barner Dalgaard and Stavros Chrysidis and Salome Kristensen and Johnny Lillelund Raun and Hanne Lindegaard and Natalia Manilo and Susanne Højmark Jakobsen and Inger Marie Jensen Hansen and Dorte Dalsgaard Pedersen and Inge Juul Sørensen and Lis Smedegaard Andersen and Jolanta Grydehøj and Frank Mehnert and Niels Steen Krogh and Merete Lund Hetland},
  year = {2020},
  journal = {Annals of the Rheumatic Diseases},
  doi = {10.1136/annrheumdis-2018-214788},
  url = {https://doi.org/10.1136/annrheumdis-2018-214788}
}

RIS

TY  - JOUR
TI  - Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
AU  - Bente Glintborg
AU  - Anne Gitte Loft
AU  - Emina Omerovic
AU  - Oliver Hendricks
AU  - Asta Linauskas
AU  - Jakob Espesen
AU  - Kamilla Danebod
AU  - Dorte Vendelbo Jensen
AU  - Henrik Nordin
AU  - Emil Barner Dalgaard
AU  - Stavros Chrysidis
AU  - Salome Kristensen
AU  - Johnny Lillelund Raun
AU  - Hanne Lindegaard
AU  - Natalia Manilo
AU  - Susanne Højmark Jakobsen
AU  - Inger Marie Jensen Hansen
AU  - Dorte Dalsgaard Pedersen
AU  - Inge Juul Sørensen
AU  - Lis Smedegaard Andersen
AU  - Jolanta Grydehøj
AU  - Frank Mehnert
AU  - Niels Steen Krogh
AU  - Merete Lund Hetland
PY  - 2020
JO  - Annals of the Rheumatic Diseases
DO  - 10.1136/annrheumdis-2018-214788
UR  - https://doi.org/10.1136/annrheumdis-2018-214788
ER  -

APA

Glintborg, B., Loft, A. G., Omerovic, E., Hendricks, O., Linauskas, A., Espesen, J., Danebod, K., Jensen, D. V., Nordin, H., Dalgaard, E. B., Chrysidis, S., Kristensen, S., Raun, J. L., Lindegaard, H., Manilo, N., Jakobsen, S. H., Hansen, I. M. J., Pedersen, D. D., Sørensen, I. J., Andersen, L. S., Grydehøj, J., Mehnert, F., Krogh, N. S., & Hetland, M. L. (2020). Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-214788

Source records

crossref · retrieved 2026-09-27T06:24:43.685Z